TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03239236

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid sequence induction t-RSI
Description: Preoxygenation via face mask, no ventilation with no PEEP until intubation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid sequence induction m-RSI-PEEP
Description: Preoxygenation via facemask with PEEP of 10 mbar. PEEP will be continued until intubation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid sequence induction m-RSI-vent
Description: Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: m-RSI-vent-cric
Description: Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cricoid Pressure
Description: Cricoid Pressure will be applied during RSI until laryngoscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthetics
Description: Induction agents will be administered as quick boluses (Propofol 2,5mg/kg total body weight, max 350mg, Fentanyl 250mcg, Rocuronium 1,2mg/kg ideal body weight).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthetics
Description: Induction agents will be administered as quick boluses (Propofol 2,5mg/kg total body weight, max 350mg, Fentanyl 250mcg, Rocuronium 1,2mg/kg ideal body weight).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthetics
Description: Induction agents will be administered as quick boluses (Propofol 2,5mg/kg total body weight, max 350mg, Fentanyl 250mcg, Rocuronium 1,2mg/kg ideal body weight).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anesthetics
Description: Induction agents will be administered as quick boluses (Propofol 2,5mg/kg total body weight, max 350mg, Fentanyl 250mcg, Rocuronium 1,2mg/kg ideal body weight).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Aspiration of gastric air via nasogastric tube
Description: A nasogastric tube will be inserted at the beginning of laparoscopy and the air from the stomach will be aspirated with a syringe. The amount of air will be measured in ml.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Aspiration of gastric air via nasogastric tube
Description: A nasogastric tube will be inserted at the beginning of laparoscopy and the air from the stomach will be aspirated with a syringe. The amount of air will be measured in ml.
Study: NCT06042439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6 weeks of exercise training (Post-training)
Description: handgrip and treadmill walking 4 days per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 6 weeks of exercise training (Post-training)
Description: handgrip and treadmill walking 4 days per week
Study: NCT05008588

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conditioned Medium
Description: Intranasal of 3 cc of conditioned medium each, for 3 days in a row

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cells
Description: Intra-parenchymal transplantation of 20x10\^6 UC-MSCs

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cells
Description: Intra-parenchymal transplantation of 20x10\^6 UC-MSCs

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Neurologic and Neutrophic Drugs
Description: Such as clopidogrel, piracetam, citicoline
Study: NCT05019040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA1010
Description: TDF as control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA1010
Description: TDF as control

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA1010
Description: TDF as control
Study: NCT05116514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case management
Description: Regular and personalized follow-up by a case manager using a case management approach, updated every 3 months
Study: NCT06400316

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acid Supplement
Description: The intervention lasts 4-week following the rheumatoid arthritis flare. It requires twice daily consumption of amino acid supplements alongside the breakfast and lunch time meals.
Study: NCT05236881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ANíMATE mobile application
Description: mHealth tool ANíMATE (Adherence, Nutrition, PhysIcal Activity, Motivation, medicAtion, Technology and Empowerment) allows the recording of data related to diet and exercise and feedback on behavior through an intelligent data analysis system.
Study: NCT06263556

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Pelvic floor exercises
Description: Patients will be informed about pelvic floor muscles functions and written material will be given for home training.~Exercise program will be planned as 1 set, 3 times per day. Each set will include 10 pelvic floor contractions. Patient will be instructed to squeeze their pelvic muscles and keep them contracted for 8 seconds. Due to fatigue and spasticity patients may experience, patients will set their own resting periods between contractions. Patients will be told to avoid contracting abdominal and gluteal muscles and avoid holding their breathe during the exercise.~Patients will be instructed to perform exercise as following:~1. Lie on your back. Take a deep breathe. Relax your abdominal muscles as you breathe out.~2. Focus on your pelvic floor muscles. Squeeze your muscles as you are trying to stop the flow of your urine and stay contracted for 8 seconds, then relax.~3. Repeat when you feel ready. You need to repeat this 10 times.~4. Repeat this exercise 3 times per day
Study: NCT05650424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal massage training
Description: please refer to group description

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal massage training
Description: please refer to group description
Study: NCT05260723

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Sit Less
Description: The Sit Less arm uses habit formation, social cognitive theory, and motivational interviewing techniques to support behavior change and includes: 1) 7 health coaching sessions to set personalized goals and review progress; 2) wearing an activPAL (thigh worn accelerometer that measures sitting time); 3) intervention tools to support behavior change (e.g., standing desk, wrist worn monitor).
Study: NCT06213324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: 0.5 mg/kg ketamine dissolved in 100 mL saline, delivered intravenously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline delivered intravenously
Study: NCT05949255

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: 10 subject will receive a probiotic daily for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 subjects will receive a placebo daily for 12 weeks.
Study: NCT05415150

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thrombolytic Agent
Description: Subjects may receive one or more of the treatment options
Study: NCT05528874

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Same intervention for both groups: glycaemic index assessment of 3 biscuits recipes
Description: Following International standards ISO 26642 guidelines, subjects (at fasting) will have their glycemia measured and after will consume a solution containing 50g of glucose and 100g of water. In the following 2 hours, glycemia and other blood parameters will be taken 6 times (at 15, 30, 45, 60, 90, and 120 minutes). This protocol is repeated twice within 3 months. After these 2 days, with the same methods, they will come to our clinic to test 3 different recipes of biscuits (characteristics are presented on request). Subjects and investigators are not blinded to these biscuits characteristics.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Same intervention for both groups: glycaemic index assessment of 3 biscuits recipes
Description: Following International standards ISO 26642 guidelines, subjects (at fasting) will have their glycemia measured and after will consume a solution containing 50g of glucose and 100g of water. In the following 2 hours, glycemia and other blood parameters will be taken 6 times (at 15, 30, 45, 60, 90, and 120 minutes). This protocol is repeated twice within 3 months. After these 2 days, with the same methods, they will come to our clinic to test 3 different recipes of biscuits (characteristics are presented on request). Subjects and investigators are not blinded to these biscuits characteristics.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crossover: Recipe 4 before recipe 5
Description: After the assessment of fasting parameters, subjects will consume recipe 4 (chocolate biscuits) and perform a 180 min curve with blood taken at 15, 30, 45, 60, 90, 120, and 180 minutes. In this case, both investigators and patients are blinded to the presence of an additional non-nutritive, non-toxic and without taste encapsulated bitter compound (artemisia absinthium), that could be present in recipe 4 or recipe 5. On the second day (with at least a week gap), patients will consume recipe 5. Questionnaires and a food diary will also be requested for subjects for lunch and dinner.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Crossover: Recipe 5 before recipe 4
Description: Same as previous group, but starting with recipe 5
Study: NCT04942938

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neubie
Description: The Neubie is a direct current neuromuscular electrical stimulation device. This system uses an exponential wave pattern to mimic the natural pattern neurologically to lengthen fibers of the sarcomere and engage force velocity of muscle with minimized protective co-contraction of nearby muscle groups. The golgi tendon and muscle spindles code for joint position and muscle/tendon stretch with 66% of fibers being intrafusal. Impacting these structures has direct impact on reticulospinal tract fibers and proprioceptive central fibers modulation of levels of spasticity. The Neubie direct current is designed to improve positioning of these stretch receptors.
Study: NCT05904249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet Based Synchronized Telerehabilitation
Description: Week 1~* Posterior capsule stretching~* Passive range of motion~* Wand exercises in supine position~* Scapular adduction exercise~* Ball rolling on the table (\<90°)~* Coldpack (15min)~Week 2~* Wand exercises while standing.~* Ball roll on wall (\>90°)~* Ball roll on the table (90°)~* Weightless External Rotation exercises~* Functional PNF movements~Week 3~* Resistive scapulothoracic strengthening~* Ball scrolling on the table (resistive)~Week 4~* Single handed ball roll on the table (\>90°)~* External rotation exercise with 0.5-1kg weight in side lying~* Strengthening exercises, shoulder in 90° scapulation for 10s~Week 5~* External rotation with 0.5-1 kg weight in side lying~* Strengthening exercises by keeping the shoulder in 90° scapulation for 10s~Week 6-8~* Dynamic hugs and push up plus~* Ball throwing and catching

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face-to-Face Rehabilitation
Description: Week 1~* Posterior capsule stretching~* Passive range of motion~* Wand exercises in supine position~* Scapular adduction exercise~* Ball rolling on the table (\<90°)~* Coldpack (15min)~Week 2~* Wand exercises while standing.~* Ball roll on wall (\>90°)~* Ball roll on the table (90°)~* Weightless External Rotation exercises~* Functional PNF movements~Week 3~* Resistive scapulothoracic strengthening~* Ball scrolling on the table (resistive)~Week 4~* Single handed ball roll on the table (\>90°)~* External rotation exercise with 0.5-1kg weight in side lying~* Strengthening exercises, shoulder in 90° scapulation for 10s~Week 5~* External rotation with 0.5-1 kg weight in side lying~* Strengthening exercises by keeping the shoulder in 90° scapulation for 10s~Week 6-8~* Dynamic hugs and push up plus~* Ball throwing and catching
Study: NCT05341804

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive and balance dual task training
Description: a cognitive and balance dual task training program involving the Internet of Thing technique software - Cognitive and Balance training Simultaneously software

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: balance training
Description: Includes static balance, dynamic balance and strength training
Study: NCT04786964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion
Study: NCT06461611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Diary Program
Description: The health diary is constructed based on the theory of health action process approach, which is used to plan and clock for self-management behaviors of adolescent patients during fixed orthodontic treatment.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Traditional Health Education
Description: Traditional health education is that the nurse orally teaches the patient about fixed orthodontic knowledge, and the patient obtains a paper information.
Study: NCT04786964

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Folic acid 350-1000 μg
Description: Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid 350-1000 μg
Description: Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin B12 1000 μg
Description: Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
Study: NCT06070805

Intervention type: OTHER
Intervention: depression
Description: The score of Hamilton Rating Scale for Depression (HAMD) is ≥8

Intervention type: OTHER
Intervention: depression
Description: The score of Hamilton Rating Scale for Depression (HAMD) is ≥8
Study: NCT05494216

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PICSI
Description: Sperm selection using PICSI dish for selecting sperm with lower DNA fragmentation index
Study: NCT04786964

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12 1000 μg
Description: Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4mg
Description: For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
Study: NCT05494216

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MACS
Description: Sperm selection using MACS for selecting sperm with lower DNA fragmentation index
Study: NCT04786964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4mg
Description: For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
Study: NCT06527456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: participation of the general practitioner
Description: participation of the general practitioner in encouraging cervical cancer screening
Study: NCT05338957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG002+HX008
Description: Administrated intravenously
Study: NCT06174363

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maxigesic
Description: For postoperative analgesia, 50 mcg of fentanyl was administered 15 minutes before the end of surgery, and IV-PCA (fentanyl 1.0 mcg/kg, ramosetron 0.3 mg, total 250cc, infusion rate 5cc/h, bolus 0.5 cc, lock-out time 15min) is started. Additionally, in the Maxigesic group, one vial of Maxigesic (acetaminophen 1000mg/ ibuprofen 300mg) is administered 15 minutes before the end of the surgery, and 2 vials of Maxigesic are added to the IV-PCA.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% saline solution
Description: For postoperative analgesia, 50 mcg of fentanyl was administered 15 minutes before the end of surgery, and IV-PCA (fentanyl 1.0 mcg/kg, ramosetron 0.3 mg, total 250cc, infusion rate 5cc/h, bolus 0.5 cc, lock-out time 15min) is started. Additionally, in the control group, the same amount of 0.9% saline solution with Maxigesic is administered.
Study: NCT06450691

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: skin biopsy and blood sampling
Study: NCT05525338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: In case of an alectinib plasmaconcentration Cmin \<435 ng/mL, determined by TDM, and manageable toxicity, the alectinib dose will be increased with 150mg BID up to a maximum of 900mg BID. In case of unacceptable toxicity (i.e. unbearable or persistent grade 2 toxicity and grade 3/4 toxicity), the alectinib dose can be reduced by 150mg BID.
Study: NCT06080776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH-1028 tablets
Description: The initial dose of SH-1028 tablets is 200 mg once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SH-1028 tablets
Description: Placebo SH-1028 tablets.
Study: NCT05633147

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaprazan glurate
Description: Investigational Medicinal Product: Linaprazan glurate (tablets).~Part I:~Linaprazan glurate in base form, 100 mg once daily Day 1 and Day 10.~Part II:~Linaprazan glurate hydrochloride (HCl), 75 mg twice daily for 13 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug drug interaction (DDI) - Clarithromycin (Part I)
Description: Index inhibitor (perpetrator drug) Clarithromycin 500 mg twice daily for 9 days (tablets).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug drug interaction (DDI) - Midazolam (Part 2)
Description: Substrate for CYP3A. Midazolam 2.5 mg once daily (2.5 mL oral solution).
Study: NCT05804006

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy followed by HIIT-REC program
Description: The experimental protocol will be preceded by 30 minutes of conventional physiotherapy followed by 15 min the rest period; then the HIIT-REC procedure will start at 4-min at 30% of the peak workload interspersed with 1-min at 70% of the peak workload at 50 rpm for weeks 1-2 and increased by approximately 5 minutes every two weeks as tolerated to reach 30 minutes from week 5 (4 to 6 repetitions). The training intensity will progress similarly by 5% peak workload two weeks as tolerated to reach 4-min at 40% peak workload interspersed with 1-min 80% peak workload from week-5
Study: NCT05942157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Drug Monitoring (TDM)
Description: Upon randomization and before the bacterial culture results are known, blood sampling will be obtained from the patient during the morning round of initial empiric antibiotic administration. PK/PD target analysis based on the clinical susceptibility breakpoints of Enterobacterales (the most prevalent organism family of DT-GNB infections in our setting) will be performed and a dosage recommendation will be communicated to the primary ID clinician. Antibiotic dosing adjustments (if any) will be made within 8 - 24 hours of the blood sampling by the Primary / Infectious Diseases clinician. In case of inappropriate dosing, where the PK/PD target is not achieved or exceeded with antibiotic side effects observed, the dosage will be increased or decreased, respectively.
Study: NCT04869709

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone Sodium Phosphate
Description: Betamethasone Sodium Phosphate 12mg IM q24h for 2 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betamethasone Sodium Phosphate
Description: Betamethasone Sodium Phosphate 12mg IM q24h for 2 doses
Study: NCT06175247

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index Diet
Description: A low glycemic diet will be initiated with dietician support and guidance.
Study: NCT06163092

Intervention type: OTHER
Description: If the CE is high, antibiotics will be given to the patients as usual practice in hospitals.
Study: NCT06013995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986326
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986326
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986326
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986326
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986326
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986326
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986326
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986326
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for BMS-986326
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for BMS-986326
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for BMS-986326
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for BMS-986326
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo for BMS-986326
Description: Specified dose on specified days
Study: NCT06537869

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: iCBT for depression
Description: iCBT depression program with minimal therapist contact offered within 14 days from inclusion and with a duration of 10-12 weeks. Contact via email or telephone every week (therapist/nurse)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCBT for depression
Description: iCBT depression program with minimal therapist contact offered within 14 days from inclusion and with a duration of 10-12 weeks. Contact via email or telephone every week (therapist/nurse)
Study: NCT06163339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cultural Formulation Interview
Description: Usual Care is enhanced with the Cultural Formulation Interview (CFI) aimed at strengthening assessment and treatment adherence